Key Takeaways
- US Commerce Secretary Howard Lutnick outlined critical developments in US trade policy, confirming a new deal with Japan featuring a lower 15% tariff on auto imports and significant Japanese investment, while pressing the European Union to fully open its markets by an August 1st deadline to avoid new tariffs.
- Hamas has provided an initial response to mediators' proposals for a Gaza agreement, with reports indicating their agreement to a deal that now awaits Israel's decision, amidst international condemnation from Paris regarding Israeli shooting operations targeting Palestinians seeking humanitarian aid.
- Johnson & Johnson (JNJ) secured two significant European Commission approvals: Imbruvica as the first targeted therapy for certain previously untreated Mantle Cell Lymphoma patients and Darzalex as the first authorized treatment for high-risk Smouldering Multiple Myeloma.
US Commerce Secretary Howard Lutnick has been a central figure in recent trade discussions, detailing the administration's aggressive push for reciprocal market access and tariff adjustments. Lutnick confirmed that a trade deal with Japan has been reached, which includes a reduced 15% tariff on Japanese auto imports to the US, down from a previously proposed 25%. As part of this agreement, Japan will commit to $550 billion in investments in the United States, with the US selecting the projects for financing, positioning Japan as the "banker, not the operator." This deal is being considered a potential model for future trade agreements, particularly with the European Union.
Regarding the European Union, Lutnick expressed confidence in securing a trade deal but reiterated an August 1st deadline for new tariffs to take effect if an agreement is not reached. He emphasized that President Trump is seeking the EU to "completely" open its markets, and if the EU accepts US products and standards, it would "move" Trump towards a favorable resolution. Lutnick is scheduled to head to Stockholm for further talks, while the EU is concurrently preparing potential countermeasures. On the technology front, Lutnick also stated that H2O controls on chips would be removed as China delivers magnets, indicating a balanced approach to trade with China, though the US will not sell its most competitive chips to the country.
In geopolitical developments, the Israeli Broadcasting Authority reported that Hamas has provided an initial response to mediators' proposals regarding a Gaza agreement. Separately, it was stated that Hamas has agreed to the Gaza agreement proposal, placing the decision now in Israel's hands. This comes as Paris condemned Israeli shooting operations that targeted Palestinians attempting to obtain humanitarian aid, highlighting ongoing humanitarian concerns in the region.
In corporate news, Thermo Fisher (TMO) provided its fiscal year adjusted earnings per share (EPS) outlook, projecting between $22.22 and $22.84, with an estimated $22.32.
Meanwhile, Johnson & Johnson (JNJ) announced two significant European Commission approvals. The EC approved Imbruvica (ibrutinib) as the first targeted therapy for certain patients with previously untreated Mantle Cell Lymphoma who are eligible for autologous stem cell transplant. This approval is supported by data from the Phase 3 TRIANGLE study, which demonstrated improved overall survival and failure-free survival. Additionally, the European Commission also approved Darzalex® (daratumumab) as the first authorized treatment for patients with high-risk Smouldering Multiple Myeloma. This approval marks a critical advancement in early intervention for the disease, offering a new treatment paradigm and potentially delaying or preventing progression to active multiple myeloma.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.